371 related articles for article (PubMed ID: 28960866)
21. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
[TBL] [Abstract][Full Text] [Related]
22. Grhl2 determines the epithelial phenotype of breast cancers and promotes tumor progression.
Xiang X; Deng Z; Zhuang X; Ju S; Mu J; Jiang H; Zhang L; Yan J; Miller D; Zhang HG
PLoS One; 2012; 7(12):e50781. PubMed ID: 23284647
[TBL] [Abstract][Full Text] [Related]
23. Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells.
Tsukasa K; Ding Q; Yoshimitsu M; Miyazaki Y; Matsubara S; Takao S
Hum Cell; 2015 Oct; 28(4):167-74. PubMed ID: 25997702
[TBL] [Abstract][Full Text] [Related]
24. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
[TBL] [Abstract][Full Text] [Related]
25. S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine.
Li T; Ren T; Huang C; Li Y; Yang P; Che G; Luo L; Chen Y; Peng S; Lin Y; Zeng L
Biochem Pharmacol; 2021 Jul; 189():114396. PubMed ID: 33359364
[TBL] [Abstract][Full Text] [Related]
26. Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition.
Mizuuchi Y; Aishima S; Ohuchida K; Shindo K; Fujino M; Hattori M; Miyazaki T; Mizumoto K; Tanaka M; Oda Y
Lab Invest; 2015 Feb; 95(2):193-206. PubMed ID: 25418581
[TBL] [Abstract][Full Text] [Related]
27. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes.
Li A; Morton JP; Ma Y; Karim SA; Zhou Y; Faller WJ; Woodham EF; Morris HT; Stevenson RP; Juin A; Jamieson NB; MacKay CJ; Carter CR; Leung HY; Yamashiro S; Blyth K; Sansom OJ; Machesky LM
Gastroenterology; 2014 May; 146(5):1386-96.e1-17. PubMed ID: 24462734
[TBL] [Abstract][Full Text] [Related]
28. ERO1L Promotes Hepatic Metastasis through Activating Epithelial-Mesenchymal Transition (EMT) in Pancreatic Cancer.
Yang J; Xu Y; Huo Y; Cai L; Hua R; Zhang J; Chen Z
J Immunol Res; 2021; 2021():5553425. PubMed ID: 33681386
[TBL] [Abstract][Full Text] [Related]
29. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling.
Meng Q; Shi S; Liang C; Liang D; Hua J; Zhang B; Xu J; Yu X
Oncogene; 2018 Nov; 37(44):5843-5857. PubMed ID: 29980787
[TBL] [Abstract][Full Text] [Related]
30. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance.
Chiou SH; Dorsch M; Kusch E; Naranjo S; Kozak MM; Koong AC; Winslow MM; Grüner BM
Sci Rep; 2018 Sep; 8(1):14008. PubMed ID: 30228296
[TBL] [Abstract][Full Text] [Related]
31. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Okada Y; Takahashi N; Takayama T; Goel A
Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
[TBL] [Abstract][Full Text] [Related]
32. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer.
Zhang KD; Hu B; Cen G; Yang YH; Chen WW; Guo ZY; Wang XF; Zhao Q; Qiu ZJ
World J Gastroenterol; 2020 May; 26(19):2349-2373. PubMed ID: 32476798
[TBL] [Abstract][Full Text] [Related]
33. Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.
Sannino G; Armbruster N; Bodenhöfer M; Haerle U; Behrens D; Buchholz M; Rothbauer U; Sipos B; Schmees C
Oncotarget; 2016 Nov; 7(45):73725-73738. PubMed ID: 27713160
[TBL] [Abstract][Full Text] [Related]
34. Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma: Characterization in a 3D-cell culture model.
Gagliano N; Celesti G; Tacchini L; Pluchino S; Sforza C; Rasile M; Valerio V; Laghi L; Conte V; Procacci P
World J Gastroenterol; 2016 May; 22(18):4466-83. PubMed ID: 27182158
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
36. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
Lu Y; Xu D; Peng J; Luo Z; Chen C; Chen Y; Chen H; Zheng M; Yin P; Wang Z
EBioMedicine; 2019 Jun; 44():403-418. PubMed ID: 31103629
[TBL] [Abstract][Full Text] [Related]
37. Girdin interaction with vimentin induces EMT and promotes the growth and metastasis of pancreatic ductal adenocarcinoma.
Wang W; Chen H; Gao W; Wang S; Wu K; Lu C; Luo X; Li L; Yu C
Oncol Rep; 2020 Aug; 44(2):637-649. PubMed ID: 32467989
[TBL] [Abstract][Full Text] [Related]
38. Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.
Faddaoui A; Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Ghani K; Bachvarov D
Cell Cycle; 2017 Apr; 16(7):693-706. PubMed ID: 28278050
[TBL] [Abstract][Full Text] [Related]
39. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells.
Wu YS; Chung I; Wong WF; Masamune A; Sim MS; Looi CY
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):296-306. PubMed ID: 27750041
[TBL] [Abstract][Full Text] [Related]
40. Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients.
Shimizu K; Chiba S; Hori Y
PLoS One; 2013; 8(11):e81283. PubMed ID: 24278411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
